» Articles » PMID: 35950469

Immunolocalization of Neurokinin 1 Receptor in WHO Grade 4 Astrocytomas, Oral Squamous Cell and Urothelial Carcinoma

Abstract

Introduction: Neurokinin-1 receptor (NK-1R) induces inflammatory reactions in peripheral tissues but its regulatory effects in target tissues is dependent on receptor signalling. Substance P (SP) has a high affinity for the NK-1R, to which it binds preferentially. We aimed to investigate the expression of NK-1R in World Health Organization (WHO) grade 4 astrocytomas as well as in oral squamous cell carcinoma (OSCC) and urothelial carcinoma, and its association with disease progression.

Material And Methods: The study included tissue samples from 19 brain astrocytomas, 40 OSCCs and 10 urothelial carcinomas. NK-1R expression was quantitatively assessed in the tumour cells using immunohistochemistry. The relationship between NK-1R expression in astrocytomas and recurrence-free interval has been explored.

Results: The results showed that the NK-1R was intensely expressed in patients with WHO grade 4 astrocytoma, OSCC and urothelial carcinoma. However, cases clinically diagnosed as a low-grade cancer showed reduced NK-1R expression.

Conclusions: NK-1R is overexpressed in all cases of WHO grade 4 astrocytoma, OSCC and urothelial carcinoma. The ubi-quitous presence of SP/NK-1R complex during tumour development and progression suggests a possible therapeutic key strategy to use NK-1R antagonist as an adjuvant therapy in the future.

Citing Articles

Radiotherapy Plus the Neurokinin-1 Receptor Antagonist Aprepitant: A Potent Therapeutic Strategy for the Treatment of Diffuse Intrinsic Pontine Glioma.

Munoz M, Rosso M Cancers (Basel). 2025; 17(3).

PMID: 39941886 PMC: 11816061. DOI: 10.3390/cancers17030520.


Glioma and Peptidergic Systems: Oncogenic and Anticancer Peptides.

Sanchez M, Mangas A, Covenas R Int J Mol Sci. 2024; 25(14).

PMID: 39063232 PMC: 11277022. DOI: 10.3390/ijms25147990.


The Repurposing of Non-Peptide Neurokinin-1 Receptor Antagonists as Antitumor Drugs: An Urgent Challenge for Aprepitant.

Covenas R, Rodriguez F, Robinson P, Munoz M Int J Mol Sci. 2023; 24(21).

PMID: 37958914 PMC: 10650658. DOI: 10.3390/ijms242115936.